LTR Pharma announced a development agreement with Strategic Drug Solutions, Inc. for development of a nasal spray for the treatment of esophageal motility disorders (difficulty in swallowing). The Australian company says that the product will be called Oroflow but did not provide any additional information. LTR is currently developing Spontan intranasal vardenafil for the treatment of erectile dysfunction and says that Oroflow is “Building on this proven technology.”
LTR Pharma Executive Chairman Lee Rodne commented, “Oroflow represents an exciting expansion of our nasal spray platform. For patients with swallowing difficulties, oral medications present obvious challenges for patients. Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief.”
Read the LTR Pharma press release
